Advertisement
Singapore markets close in 2 hours 2 minutes

  • Straits Times Index

    3,265.44
    +40.27 (+1.25%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,786.57
    +274.88 (+1.66%)
     

  • FTSE 100

    8,023.87
    +128.02 (+1.62%)
     

  • Bitcoin USD

    66,371.66
    +7.59 (+0.01%)
     

  • CMC Crypto 200

    1,402.08
    -12.68 (-0.90%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • Dow

    38,239.98
    +253.58 (+0.67%)
     

  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     

  • Gold

    2,315.90
    -30.50 (-1.30%)
     

  • Crude Oil

    83.02
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • FTSE Bursa Malaysia

    1,563.89
    +4.30 (+0.28%)
     

  • Jakarta Composite Index

    7,114.30
    +40.48 (+0.57%)
     

  • PSE Index

    6,514.03
    +69.95 (+1.09%)
     

Earnings Estimates Moving Higher for AMAG Pharmaceuticals (AMAG): Time to Buy?

Zacks Equity Research

AMAG Pharmaceuticals, Inc. (AMAG) is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMAG’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that AMAG Pharmaceuticals could be a solid choice for investors.

Current Quarter Estimates for AMAG

In the past 30 days, 1 estimate has gone higher for AMAG Pharmaceuticals. The trend has been pretty favorable too, with estimates moving from a loss of 12 cents per share 30 days ago to earnings of 1 cent a share today.

Current Year Estimates for AMAG

Meanwhile, AMAG Pharmaceuticals’ current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to no downward revision. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 60 cents per share 30 days ago to a loss of 30 cents per share today, an increase of 50.0%.

Bottom Line

The stock has also started to move higher lately, adding 13.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




AMAG PHARMACEUTICALS INC (AMAG): Free Stock Analysis Report


Zacks Investment Research